DNTH · Dianthus Therapeutics, Inc. /DE/ · Exempt Offerings
$89.91
+1.86 (+2.11%)
At close · Oct 1
Return incl. dividend (before tax)
Going-concern doubt
— cleared Aug 4, 2026
The latest filing states the doubt was alleviated.
“In accordance with Accounting Standards Update No. 2014-15, Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern (Subtopic 205-40), the Company has evaluated whether there are certain conditions and events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern within one year after the date that the accompanying unaudited condensed consolidated financial statements were issued (the "issuance date") As of the issuance date, the Company expects that its existing cash, cash equivalents and investments on hand will be sufficient to fund its obligations as they become due for at least twelve months beyond the issuance date.”View the 10-Q filed Aug 4, 2026
Market Cap
$5.23B
Shares
55.93M
Volume · Oct 1
124.17K
Avg daily vol (3M)
833.35K
Private capital raises reported to the SEC on Form D under Regulation D, showing the offering size, amount sold, minimum investment and number of investors. Public operating companies rarely raise capital this way, so this page is often empty.
No Exempt Offerings
No Form D exempt-offering notices are available for this stock yet.